This is the case of NUCC-390, an agonist of CXCR4 receptor, which promotes the regeneration of nerve terminals affected by neurotoxic PLA2s that act presynaptically [115], or possible therapies to improve skeletal muscle regeneration after venom-induced myonecrosis [116,117]. The gene discussed is PLA2G2A; the disease is gas gangrene.